Eye on Washington

Both monthly migraine days and headache days were reduced vs placebo in patients aged 6 to 17 years.

In the study through 76 weeks, no new risks were observed with once-daily upadacitinib (15 mg or 30 mg).

If approved, SL1009 has the potential to be the first approved medication for PDCD, and would be available as an oral solution.

Colleen Sloan, PA-C, RDN, unpacks the essential nutrient children are missing in their diets and how providers and parents can start implementing.